Eden Research (AIM:EDEN), the AIM-listed biopesticide developer, has secured regulatory approval for its Mevalone biofungicide in Slovakia and Egypt.
The Slovak approval, granted in July by the Central Control and Testing Institute of Agriculture, covers use on grapes and pome fruit and will be commercialised by distribution partner Biocont.
Slovakia's six wine-growing regions cover approximately 14,400 hectares and produced around 332,000 hectolitres of wine last year, with Botrytis cinerea the principal late-season disease threat as EU restrictions on conventional chemistry tighten.
In Egypt, the product has been approved for use on grapes against Botrytis with no pre-harvest interval required, meaning growers can apply it immediately before harvest.
That matters for an industry built on exports: Egypt produced approximately 1.59 million tonnes of table grapes in the 2024/25 marketing year, with the European Union its principal destination and strict residue limits governing what growers can apply close to harvest.
Registration was secured by Sipcam Oxon, an Eden shareholder, and will be commercialised through its subsidiary Sipcam Inagra Egypt.
It is Mevalone's first authorisation in North Africa, with Eden and Sipcam now pursuing registrations in Algeria, Tunisia and Morocco.
"Egypt marks the first authorisation in North Africa for Mevalone and with no pre-harvest interval on the label, it provides a strong advantage for growers supplying highly regulated export markets", said chief executive Sean Smith.
News Intelligence what this means for the company
Eden Research secured regulatory approvals for Mevalone in Slovakia and Egypt, with the Egypt clearance notably carrying no pre-harvest interval—a material advantage for growers exporting to the EU under strict residue limits. Egypt's 1.59 million tonnes of annual table grape production, with the EU as its principal export destination, represents a significant addressable market where the no-interval label removes a competitive constraint versus conventional chemistry.
- Sipcam Oxon, Eden's shareholder and the registrant in Egypt, now has commercial incentive to drive Mevalone adoption in its subsidiary Sipcam Inagra Egypt's distribution network, potentially accelerating revenue recognition.
- The Slovakia approval via Biocont establishes a beachhead in EU wine production (14,400 hectares across six regions) where Botrytis pressure is rising as conventional fungicide restrictions tighten, validating Mevalone's positioning in regulated markets.
These are early-stage geographic expansions that validate Mevalone's regulatory pathway and market fit in export-focused agriculture, but neither approval yet demonstrates commercial traction or revenue contribution. The Egypt no-interval label is a genuine competitive differentiator, but success depends on grower adoption and Sipcam's commercialisation execution.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
